EQL PHARMA AB (7JK) — Cash Flow Reinvestment Rate
EQL PHARMA AB (7JK) has a Cash Flow Reinvestment Rate of 1.03x as of March 2026, reinvesting €17.22 Million (capex €17.22 Million ) from operating cash flow of €16.79 Million. See EQL PHARMA AB free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
EQL PHARMA AB Cash Flow Reinvestment Rate (2022–2026)
Historical reinvestment intensity for EQL PHARMA AB across 3 annual periods. For the full cash flow conversion analysis, see EQL PHARMA AB operating cash flow efficiency.
Annual Cash Flow Reinvestment Rate for EQL PHARMA AB (2022–2026)
Year-by-year capital reinvestment analysis for EQL PHARMA AB. See EQL PHARMA AB (7JK) financial flexibility to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2026 | 2.37x | €67.24 Million | €28.36 Million | €67.24 Million | ▲ +219.2% |
| 2023 | 0.74x | €20.51 Million | €27.62 Million | €20.51 Million | ▲ +40.6% |
| 2022 | 0.53x | €22.09 Million | €41.83 Million | €22.09 Million | — |